Potential role for interleukin-1 in the cardio-renal syndrome

Eur J Heart Fail. 2019 Mar;21(3):385-386. doi: 10.1002/ejhf.1403. Epub 2019 Jan 22.

Affiliations

¹ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
² VCU Pauley Heart Center, Richmond, VA, USA.
³ Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA.
⁴ Department of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, VA, USA.

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, N.I.H., Extramural

MeSH terms

Cardio-Renal Syndrome* / drug therapy
Cardio-Renal Syndrome* / immunology
Cardio-Renal Syndrome* / physiopathology
Female
Heart Failure* / drug therapy
Heart Failure* / metabolism
Heart Failure* / physiopathology
Humans
Immunosuppressive Agents / administration & dosage
Inflammation / metabolism*
Interleukin 1 Receptor Antagonist Protein / administration & dosage*
Interleukin-1* / antagonists & inhibitors
Interleukin-1* / metabolism
Kidney Function Tests / methods
Male
Middle Aged
Monitoring, Immunologic / methods
Renal Insufficiency* / drug therapy
Renal Insufficiency* / metabolism
Renal Insufficiency* / physiopathology
Treatment Outcome

Substances

Immunosuppressive Agents
Interleukin 1 Receptor Antagonist Protein
Interleukin-1

Grants and funding